Effective Seizure Management Elevates Demand for Phenobarbital; Global Market Set to Expand with Steady 5% CAGR
DUBLIN, Sept. 5, 2023 /PRNewswire/ -- The "Phenobarbital Market, By Indication, By Dosage Form, By Distribution Channel, and By Geography- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering. The global phenobarbital... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 5, 2023 Category: Pharmaceuticals Tags: MRR Source Type: news
Community pharmacy quality scheme: high risk medicines audit
This report details the results and findings of the 2019/20 high risk medicines audit report for lithium, methotrexate, amiodarone and phenobarbital and makes recommendations on further actions. (Source: NHS Networks)
Source: NHS Networks - March 21, 2023 Category: UK Health Source Type: news
Suicide by taking phenobarbital and scopolamine: a case report - 董, 张, 刘.
[Abstract unavailable]
Language: zh... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Sun Pharmaceutical launches phenobarbital sodium injection in US
"The launch of SEZABY is an exciting addition to our growing portfolio of specialty branded products in the US," Sun Pharma CEO North America Abhay Gandhi said. He further said, "As the first and only FDA-approved product for the treatment of seizures in term and preterm infants, SEZABY has the potential to make a meaningful difference in the lives of patients and their families, and we are proud to be able to provide physicians with this new treatment option." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Sezaby (phenobarbital sodium powder for injection) for the Treatment of Neonatal Seizures
First and only product approved for treating seizures in neonatal patients
Mumbai, India, November 18, 2022– Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Ltd. today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2022 Category: Drugs & Pharmacology Source Type: news
Class 2 Medicines Recall: Bristol Laboratories Limited, Phenobarbital 60 mg Tablets
Bristol Laboratories Limited is recalling a specified batch of this product as a precautionary measure due to low dissolution test results reported during ongoing stability studies.
Further informati (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 13, 2022 Category: Drugs & Pharmacology Source Type: news
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first ...
Source: Johnson and Johnson - March 30, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
TITUSVILLE, N.J., March 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a label update for CABENUVA (cabotegravir and rilpivirine), giving healthcare professionals and people living with human immunodeficiency virus (HIV-1) in the U.S. the option to start this once-monthly or every-two-month injectable treatment without the need for the oral lead-in phase (daily cabotegravir and rilpivirine tablets, taken for one month prior to initiation of cabotegravir and rilpivirine injections).1 Clinical data demonstrated the regimen di...
Source: Johnson and Johnson - March 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Post-It Pearls: Phenobarbital for Alcohol Withdrawal Symptoms
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - March 1, 2022 Category: Emergency Medicine Tags: Post-It Pearls Source Type: news
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter [c/ml]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either rilpivirine or cabotegravir. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janss...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Getting a Prescription to Die Remains Tricky Even As Aid-in-Dying Bills Gain Momentum Across the U.S.
Linda Heim knew her dad didn’t plan to wait for the cancer to kill him. For decades, he’d lived in Montana, which they’d thought was one of the few places where terminally ill people could get a prescription to end their life.
After two years of being sick, Heim’s dad got the diagnosis in 2019: stage 4 kidney cancer. His physician offered treatments that might extend his life by months. Instead, the 81-year-old asked the doctor for help dying. Heim said her parents left the appointment in their hometown of Billings with two takeaways: The legality of medically assisted death was questionable in Mont...
Source: TIME: Health - March 29, 2021 Category: Consumer Health News Authors: Katheryn Houghton / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both monthly dosing an...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months
TITUSVILLE, N.J., February 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for the expanded use of CABENUVA (consisting of Janssen’s long-acting rilpivirine and ViiV Healthcare’s cabotegravir). The sNDA seeks to expand the CABENUVA label to include administration every two months for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per mL) on a stable regimen,...
Source: Johnson and Johnson - February 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Acute phenobarbital poisoning for the management of seizures in new-borns and children; a systematic literature review - Ghorani-Azam A, Balali-Mood M, Riahi-Zanjani B, Darchini-Maragheh E, Sadegh M.
OBJECTIVES: While phenobarbital (PB) is commonly used for the management of seizures in newborns and pediat-rics, its administration may accompany with acute poisoning. We aimed to review the literature to find out the frequency of PB poisonings in newborn... (Source: SafetyLit)
Source: SafetyLit - December 11, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
